4 Stocks Dragging In The Health Services Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 164 points (-1.0%) at 16,209 as of Thursday, Jan. 23, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 966 issues advancing vs. 2,022 declining with 119 unchanged.

The Health Services industry currently sits down 0.7% versus the S&P 500, which is down 0.9%. On the negative front, top decliners within the industry include Mindray Medical International Limited ADR r ( MR), down 4.4%, Agilent Technologies ( A), down 2.0%, DaVita HealthCare Partners ( DVA), down 1.4%, Thermo Fisher Scientific ( TMO), down 1.4% and Boston Scientific ( BSX), down 1.2%. A company within the industry that increased today was Smith & Nephew ( SNN), up 0.7%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Becton Dickinson ( BDX) is one of the companies pushing the Health Services industry lower today. As of noon trading, Becton Dickinson is down $0.88 (-0.8%) to $110.68 on light volume. Thus far, 256,824 shares of Becton Dickinson exchanged hands as compared to its average daily volume of 750,200 shares. The stock has ranged in price between $110.32-$111.39 after having opened the day at $111.39 as compared to the previous trading day's close of $111.56.

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company's BD Medical segment produces medical devices that are used in various healthcare settings. Becton Dickinson has a market cap of $21.6 billion and is part of the health care sector. The company has a P/E ratio of 23.9, above the S&P 500 P/E ratio of 17.7. Shares are up 1.0% year-to-date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Becton Dickinson a buy, 3 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Becton Dickinson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Becton Dickinson Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Zimmer Holdings ( ZMH) is down $1.00 (-1.0%) to $95.41 on light volume. Thus far, 358,304 shares of Zimmer Holdings exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $95.35-$96.89 after having opened the day at $96.37 as compared to the previous trading day's close of $96.41.

Zimmer Holdings, Inc., through its subsidiaries, engages in the design, development, manufacture, and marketing of orthopedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. Zimmer Holdings has a market cap of $16.5 billion and is part of the health care sector. The company has a P/E ratio of 24.4, above the S&P 500 P/E ratio of 17.7. Shares are up 3.7% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Zimmer Holdings a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates Zimmer Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Zimmer Holdings Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Covidien ( COV) is down $0.97 (-1.4%) to $67.12 on average volume. Thus far, 1.1 million shares of Covidien exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $66.79-$67.82 after having opened the day at $67.79 as compared to the previous trading day's close of $68.09.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $30.8 billion and is part of the health care sector. The company has a P/E ratio of 20.1, above the S&P 500 P/E ratio of 17.7. Shares are down 0.0% year-to-date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Aetna ( AET) is down $0.37 (-0.5%) to $70.24 on light volume. Thus far, 691,842 shares of Aetna exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $69.96-$70.53 after having opened the day at $70.16 as compared to the previous trading day's close of $70.61.

Aetna Inc. operates as a diversified health care benefits company in the United States. The company operates in three segments: Health Care, Group Insurance, and Large Case Pensions. Aetna has a market cap of $25.8 billion and is part of the health care sector. The company has a P/E ratio of 14.2, below the S&P 500 P/E ratio of 17.7. Shares are up 2.9% year-to-date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Aetna a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Aetna as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, attractive valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Aetna Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

Carnival Corp., Hain Celestial, Becton Dickinson: 'Mad Money' Lightning Round

Carnival Corp., Hain Celestial, Becton Dickinson: 'Mad Money' Lightning Round

Good Reasons for Stocks to Soar: Cramer's 'Mad Money' Recap (Tuesday 12/2/18)

Good Reasons for Stocks to Soar: Cramer's 'Mad Money' Recap (Tuesday 12/2/18)

Edwards Lifesciences, AeroVironment, Oshkosh Truck: 'Mad Money' Lightning Round

Edwards Lifesciences, AeroVironment, Oshkosh Truck: 'Mad Money' Lightning Round

Beware This Bull Stampede: Cramer's 'Mad Money' Recap (Tuesday 10/3/17)

Beware This Bull Stampede: Cramer's 'Mad Money' Recap (Tuesday 10/3/17)